View this email in your browser
A year to remember
BIA Separations is proud that another great year full of achievement’s is coming to an end.  In honor of our achievements, we have prepared a collection of some of the most notable events and accomplishment that happened in this year.
Sartorius Creates a Premium Gene Therapy and Vaccine Portfolio with the Acquisition of BIA Separations
We mark one year since the Sartorius merger. With this acquisition Sartorius expanded its downstream processing and analytics offerings to complement its upstream capabilities. Specifically, this merge has strengthened Sartorius’ offerings in the gene therapy and vaccine markets for production of AAV, mRNA and pDNA, among others, while BIA Separations confirmed its primacy as a center of excellence for gene therapy within the Sartorius group. Click here for more details.
 Our expanded production facilities were officially opened in May
On Friday, May 28, we officially opened our expanded production site which doubled our available space for manufacturing and labs. This particularly enhanced our unique offering for the manufacturing of gene therapies and other advanced therapies and will enable our business to develop and grow to meet the requirements of our expanding industry. Additionally, with this our growth is not completed, as we will increase production capacities in Q1 2022, when Building C will be officially opened and functional.
Introducing PATfix pDNA – next frontier of pDNA analytics
 This past June we successfully launched one of our most important products. PATfix pDNA analytical platform is providing reliable in-process control for pDNA process development and production and it was designed to give “at-line” reliable insight during Process Development (PD) and production of pDNA. If you are not familiar with it yet, click here and read more about this versatile HPLC system.
BioNet and Sartorius’ company BIA Separations collaborate on production process development of mRNA vaccines
On November 2nd, together with BioNet Asia, we announced that the new process has been successfully applied to the production of mRNA in the fight against COVID-19. Our expertise in chromatographic columns for mRNA purification combined with BioNet’s knowledge in the product development of genetic vaccines have, since early 2021, enabled both teams to collaborate on the optimization and upscale of a high-yield mRNA production process. Read more.
New year, new opportunities
This year's successes motivate us to achieve even more, which is why we set high goals for 2022. Here are just a few of the milestones we want to reach:
  • Automated production of 40 L units
  • Launch of new product line (96-well plate program)
  • Set-up of our new business development team
  • Introduction of some new chemistries.
For us, the sky is the limit. To follow our fast pace, we recommend that you visit our website regularly, subscribe to our newsletters and stay tuned for more information!
Be a part of MSS2022
Monoliths. Vaccines. Gene therapy.

It is our sincere pleasure to invite you to MSS2022, the 9th Monolith Summer Symposium. Our mission is to spread the knowledge on the evolution and applications of monolith technology. Join us to leave your mark and add a pebble to this remarkable mosaic we are building together.
Highlighted Speakers:
  • Robert Hodge, TheraPartners, LLC, USA
  • Thomas Muster, BlueSky Vaccines, Austria
  • Matjaž Peterka, Cobik, Slovenia
  • Jared Davis, Providence Therapeutics, Canada
  • Kazuhiro Oka, Baylor College of Medicine, USA
  • David Dobnik, NIB, Slovenia
Early bird registration: Pay by February 28th 2022 and take advantage of a 30% discount!
Copyright © 2021 BIA Separations, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp